| Q90598550 | A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382 |
| Q38943401 | A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells. |
| Q54065729 | Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. |
| Q37393002 | Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant |
| Q28359567 | Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells |
| Q28077245 | Antiestrogens: structure-activity relationships and use in breast cancer treatment |
| Q35356178 | Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer |
| Q54065301 | Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. |
| Q57107345 | Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence |
| Q36618242 | Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. |
| Q91843606 | Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer |
| Q34277832 | Fulvestrant |
| Q35690167 | Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy |
| Q35750078 | Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action |
| Q36998209 | HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. |
| Q43704085 | Identification of two estrogen regulated genes associated with growth regulation of human breast cancer. |
| Q54028727 | Increased expression of cytochrome p450 1A1 and 1B1 genes in anti-estrogen-resistant human breast cancer cell lines. |
| Q36540703 | Induction of acquired resistance to antiestrogen by reversible mitochondrial DNA depletion in breast cancer cell line |
| Q61798981 | Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells |
| Q41463841 | Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer |
| Q40661179 | N-Alkoxypyrazoles as biomimetics for the alkoxyphenyl group in tamoxifen |
| Q39360262 | NFκB signaling is important for growth of antiestrogen resistant breast cancer cells. |
| Q59289328 | New endocrine treatments for breast cancer: biological and clinical aspects |
| Q44515973 | Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer |
| Q41083185 | Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness |
| Q91322415 | Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells |
| Q37952234 | Role of fulvestrant in the management of postmenopausal breast cancer |
| Q55298688 | SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. |
| Q40522824 | Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment |
| Q41380080 | Steroid hormones and cancer: (II) Lessons from experimental systems |
| Q38353763 | Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. |
| Q27852459 | TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. |
| Q47582689 | The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer |
| Q36013029 | The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance |
| Q40453538 | Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. |